

## MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES BUREAU OF COMMUNICABLE DISEASE CONTROL AND PREVENTION **TUBERCULOSIS (TB) RISK ASSESSMENT**

PATIENT'S NAME		DATE OF BIRTH			DATE				
ADDRESS						TELEPHONE	NUMBER		
A. PLEASE ANSWER THE FOLLOWING QUESTIONS (SECTIONS A & B TO BE COMPLETED BY PATIENT)									
HAVE YOU EVER HAD A POSITIVE MANTOUX TUBERCULIN SKIN TEXT (TST)?				HAVE YOU EVER BEEN VACCINATED WITH BCG?					
HAVE YOU EVER HAD A POSITIVE INTERFERON GAMMA RELEASE ASSAY (IGRA) TEST?				HAVE YOU EVER BEEN DIAGNOSED WITH OR TREATED FOR TB DISEASE?					
B. TB RISK ASSESSMENT									
HAVE YOU EVER HAD CLOSE CONTACT WITH ANYONE WHO WAS SICK WITH TUBERCULOSIS? HAVE YOU EVER TRAVELED TO ONE OR MORE OF THE COUNTRIES LISTED BELOW?									
□YES □NO	YES [	YES NO If yes, please CHECK the country/ies below							
WERE YOU BORN IN ONE OF THE COUNTRIES LISTED BELOW?				WHAT YEAR DID YOU ARRIVE IN THE UNITED STATES?					
Afghanistan	China	Guam	Maldives		Poland		🗆 Тодо		
Algeria	Colombia	🗌 Guyana	🗌 Mali		Portugal		🗌 Tokelau		
🗆 Angola	Comoros	🗌 Haiti	🗌 Marshall Is	slands	🗌 Qatar		🗌 Tonga		
🗆 Anguilla	Congo	Honduras	🗆 Mauritania	a	🗌 Romania		🗌 Trinidad & Tobago		
🗆 Argentina	Congo DR	Hungary	Mauritius		Russian Fede	eration	🗌 Tunisia		
Armenia	Cote d'Ivoire	🗌 India	Mexico		Rwanda		Turkey		
🗌 Azerbaijan	Croatia	🗌 Indonesia	Micronesia		St. Vincent &	The	Turkmenistan		
Bahrain	Djibouti	Iran	Moldova-F	Rep.	Grenadines		Turks & Caicos Islands		
Bangladesh	Dominica	🗌 Iraq	🗌 Mongolia		Sao Tome &		Tuvalu		
Belarus	Dominican Republic	∐ Japan	Morocco		Saudi Arabia		🗌 Uganda		
Belize	Ecuador	Kazakhstan	Mozambiq	que	Senegal		Ukraine		
	Egypt	Kenya	Myanmar		Serbia		Uruguay		
Bhutan Bolivia	El Salvador	☐ Kiribati ☐ Korea-DPR	□ Namibia □ Nauru			ierra Leorie	Uzbekistan		
Bosnia & Herzegovina	Equatorial Guinea	Korea-Republic	Nauru     Nepal		Solomon Isla	nds	Venezuela		
Botswana						100	□ Viet Nam		
	Ethiopia	Kyrgyzstan		l	South Africa		Wallis & Futuna Islands		
Brunei Darussalam			□ Nigeria		Sri Lanka		Vemen		
	French Polynesia				□ Sudan		Zambia		
Burkina Faso	Gabon	Lesotho	N. Mariana	a Islands	Sudan-South				
Burundi	Gambia	Liberia	Pakistan		Suriname				
🗆 Cambodia	🗌 Georgia	🗌 Libyan Arab Jamihirya	🗌 Palau		Syrian Arab F	Republic			
Cameroon	Ghana	Lithuania	🗌 Panama		Swaziland				
Cape Verde	Greenland	Macedonia-TFYR	🗌 Papua Ne		🗌 Tajikistan				
Central African Rep.	Guatemala	Madagascar	Paraguay		Tanzania-UR				
Chad	Guinea	🗌 Malawi	Peru		Thailand				
Chile	🗌 Guinea-Bissau	🗌 Malaysia	Philippines	S	Timor-Leste				
	GANIZATION GLOBAL TUBERCU DATES, REFER TO WWW.WHO.IN		RT 2013, COUN	NTRIES WITH TU	BERCULOSIS INC	IDENCE RATE	ES OF > 20 CASES PER 100,000		
HAVE YOU EVER HAD AN ABNO		/E OF TB?		ARE YOU HIV POSITIVE?					
∐yes ∐no ∐no	) RESPONSE		LIYES L		O RESPONS	E			
ARE YOU IMMUNOSUPPRESSED (TAKING AN EQUIVALENT OF >15 MG/DAY OF PREDNISONE FOR ≥ 1 MONTH, OR CURRENTLY TAKING PRESCRIPTION ARTHRITIS MEDICATION)?									
YES       NO       NO RESPONSE         ARE YOU A RESIDENT, EMPLOYEE, OR VOLUNTEER IN A HIGH-RISK CONGREGATE SETTING (E.G., CORRECTIONAL FACILITIES, NURSING HOMES, HOMELESS SHELTERS, HOSPITALS, AND OTHER HEALTH CARE FACILITIES)?									
DO YOU HAVE ANY MEDICAL CONDITIONS SUCH AS DIABETES, SILICOSIS, HEAD, NECK, OR LUNG CANCER, HEMATOLOGIC OR RETICULOENDOTHELIAL DISEASE SUCH AS HODGKIN'S DISEASE OR LEUKEMIA, END STAGE RENAL DISEASE, INTESTINAL BYPASS OR GASTRECTOMY, CHRONIC MALABSORPTION SYNDROME, LOW BODY WEIGHT, (I.E., 10% OR MORE BELOW IDEAL)?									
VIED REINER END STAGE REINEL DISEASE, INTESTINAL DIFASS ON GASTRECTOWN, CHRONIC MALADSONFTION STINDHOME, LOW BODT WEIGHT, (I.E., 10% ON MICHE BELOW IDEAL)?									
DO YOU HAVE A COUGH LASTING 3 WEEKS OR LONGER, CHEST PAIN, WEAKNESS OR FATIGUE, WEIGHT LOSS, CHILLS, FEVER AND/OR NIGHT SWEATS?									
		entation or falsification and the	at the information	on given by me i	is true and compl	ata ta tha ha	est of my knowledge and belief.		
							, ,		
PATIENT SIGNATURE (REQUIRED) DATE									

## C. MEDICAL EVALUATION (SECTION C TO BE COMPLETED BY HEALTH CARE PROVIDER-IF NEEDED)

Health Care Provider: If the answer to any of the TB Risk Assessment questions in Section B is YES or NO RESPONSE, proceed with additional medical evaluation as appropriate. Additional evaluation may include one or more of the following: TST, IGRA, sign and symptom review, chest x-ray, or sputum collection. If the patient is immunosuppressed and no previous TB test is documented, an IGRA is recommended.

1. Tuberculin Skin Test (TST) Please provide a 2-step TST for those at high risk that have no documentation of a previous TST: Administer 1st step TST today and read in 48-72 hours, if the 1st step TST is positive, document the results in millimeters (mm) of induration and follow the evaluation steps for a positive TST. If the 1st step TST is negative, document the results in mm of induration. Induration should be measured in transverse diameter; if no induration write "0" mm. The TST interpretation* should be based on mm of induration as well as risk factors, not erythema (redness). Place a 2-step TST in one to three weeks after the first TST was read and recorded. The 2-step TST should be read in 48-72 hrs and then follow the documentation procedures as outlined above.								
DATE GIVEN		DATE READ						
RESULT		*INTERPRETATION						
	of Induration							
DATE GIVEN DATE READ								
RESULT	of Induration							
		-						
	N GUIDELINES (PLEASE CHECK ALL 1	HAI APPLY)						
>5 mm is Positive:          Recent close contact of an individual with infectious TB.         Persons with fibrotic changes on a prior chest x-ray consistent with past TB disease.         Organ transplant recipients.         Immunosuppressed persons taking ≥ 15mg/d of prednisone for ≥ 1 month; taking a TNF-α antagonist.         Persons with HIV/AIDS.         >10 mm is Positive:         Persons born in a high prevalence country or who resided in one for a significant amount of time.         History of illicit drug use.         Mycobacteriology laboratory personnel.         History of resident, worker or volunteer in high-risk congregate settings.         Persons with the following clinical conditions: silicosis, diabetes mellitus, chronic renal failure, leukemias and lymphomas, head, neck or lung cancer, low body weight (>10% below ideal), gastrectomy or intestinal bypass, chronic malabsorption syndromes.         Children <4 years of age.								
2. Interferon Gamma	Release Assay: (IGRA: Please check th	e IGRA that is used)						
	2 .	,	DATE OBTAINED					
RESULT	RESULT							
T-Spot	RESULT	/Equivocal	DATE OBTAINED					
Other	RESULT	1	DATE OBTAINED					
I								
	ired if TST or IGRA is positive)							
DATE OF CHEST X-RAY	DATE OF CHEST X-RAY RESULT ABNORMAL CHEST X-RAY INTERPRETATION ABNORMAL CHEST X-RAY INTERPRETATION							
4. Sputum Collection	: If the patient has a positive TST or le	GRA and a productive cough > 3 weeks, with or nust be at least eight (8) hours apart with a minimum of 2 milli	without hemoptysis,					
1. DATE OBTAINED	SMEAR RESULT	CULTURE RESULT						
2. DATE OBTAINED	SMEAR RESULT	CULTURE RESULT						
3. DATE OBTAINED	SMEAR RESULT	CULTURE RESULT	CULTURE RESULT					
An isolate on any positive m	An isolate on any positive mycobacterium cultures should be sent to the Missouri State Public Health Laboratory.							
I HAVE REVIEWED THE ABOVE INFORMATION WITH THE PATIENT AND DEEMED								
□ No further evaluation needed □ Further evaluation is needed								
HEALTH CARE PROVIDER SIGNAT	DATE							
All positive TST, IGRA, chest x-ray, smear and culture results suggestive of tuberculosis disease or latent tuberculosis infection should be reported to the Missouri Department of Health and Senior Services (fax number: 573-526-0235) or your local public health agency using this form. If you have any questions, please contact the Bureau of Communicable Disease Control and Prevention at 573-751-6113.								